1. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
- Author
-
Brittany McCreery, Bryan Lewis, Naomi B. Haas, Lakshminarayanan Nandagopal, Mary A. Dwyer, Angela D. Motter, Christos Kyriakopoulos, Ajjai Alva, Maria I. Carlo, Phillip M. Pierorazio, M. Dror Michaelson, Sundhar Ramalingam, Brandon Manley, Clayton Lau, Lee Ponsky, Eric Jonasch, Neeraj Agarwal, David C. Madoff, Elizabeth R. Plimack, Bradley G. Somer, Jeffrey A. Sosman, Robert J. Motzer, Amir Mortazavi, Steven L. Hancock, Shawna L. Boyle, Elaine T. Lam, Ithaar Derweesh, Brian Shuch, Katy Beckermann, Arpita Desai, Saby George, Brian A. Costello, Zachary L. Smith, John L. Gore, and Toni K. Choueiri
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,MEDLINE ,Treatment options ,urologic and male genital diseases ,medicine.disease ,Systemic therapy ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Renal cell carcinoma ,030220 oncology & carcinogenesis ,Carcinoma ,Medicine ,030212 general & internal medicine ,business ,Intensive care medicine ,Stage iv ,Kidney cancer ,Genetic testing - Abstract
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.
- Published
- 2020